Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Taking an innovative approach to applying artificial intelligence (AI) to medical imaging, Quibim is designing predictive panels to enable healthcare providers to improve patient outcomes.
TeselaGen’s artificial intelligence-enabled operating system for designing, building, and optimizing bio-based products is driving innovation across the biotechnology sector.
Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.
Enveda Biosciences combines machine learning and complex naturally-based libraries of compounds to find potential hits and leads for previously undruggable targets and to uncover novel mechanisms of action.
POLARISqb is slashing the timeframes and costs of drug discovery by using the unique processing power of quantum technology to identify the best lead compounds for drug development.
By integrating artificial intelligence, three-dimensional and multi-organ technology, Quris-AI is developing a ground-breaking clinical-prediction platform with the potential to revolutionize disease modelling and personalized medicine.
A next-generation diagnostic test developed by Haystack Oncology detects the presence of minimal residual disease in early-stage cancer patients after curative-intent surgery. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA in blood—clinicians can make more-informed decisions to help their patients achieve better outcomes.
The Korea Drug Development Fund (KDDF), through its investment and support of the biopharma sector, translates cutting-edge science into patient benefits and market opportunities.
LR 09, a metabolic immune-checkpoint inhibitor that can initiate graft-versus-leukemia effect in relapsed allogeneic stem-cell transplant (SCT) patients, could become the new standard of care for leukemia.
Ellipses Pharma’s KOL-enabled cloud-based platform is crowdsourcing expert insight from oncologists worldwide to create tailored opportunities for developing drug candidates.
With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.
Affivant Sciences is developing tetravalent, bispecific antibodies that can recruit multiple innate immune-cell types to attack a range of challenging cancers.
Strike Pharma has developed new affinity-based linkers for optimized delivery of tumor-specific immunogenic peptides to immune cells, creating more efficacious personalized immunotherapies with fewer side effects.
Eterna Therapeutics is using state-of-the-art messenger RNA (mRNA) technology to develop cell and gene therapies for cancer and a wide range of other indications.
The precision medicine services company Oncolines B.V. is accelerating cancer drug development by identifying drug response biomarkers in over 200 genetically characterized cancer cell lines.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.
